The Top FCA Developments Of 2017
Client Alert | less than 1 min read | 02.02.18
From decisions on small business fraud to interpretations of the reverse FCA, 2017 was another busy year for False Claims Act developments. In a "Feature Comment" published in The Government Contractor, C&M attorneys highlight top developments from 2017 on key issues such as original source requirements, DOJ’s potential dismissal of meritless qui tams, statistical sampling, and perhaps most significantly, the continued evolution of the case law in the wake of the Supreme Court’s landmark implied certification and materiality decision in Escobar.
Contacts
Insights
Client Alert | 5 min read | 04.13.26
EU Pharma Package: Global (Orphan) Marketing Authorization Compromise Proposal
In our fifth alert in this EU Pharma Package Series, we provided an analysis of the background and ongoing legal debates regarding the concept of the global marketing authorization (GMA). We discussed in particular the missed opportunities in the Pharma Package to further codify and clarify the GMA, in view of its central role in determining the regulatory data protection (RDP) rights of a medicinal product.
Client Alert | 4 min read | 04.13.26
Client Alert | 4 min read | 04.10.26
CMS Finalizes Rate Notice for Medicare Parts C and D (CY 2027)
Client Alert | 2 min read | 04.10.26
